Picroliv Drug (E)
Researchers from CSIR's Central Drug Research Institute, Lucknow, have developed a drug named 'Picroliv' against non-alcoholic fatty liver disease from the extract of the Kutki or Picrorhiza kurroa. Researchers say that this drug, developed from a natural resource, can reduce the amount of fat in the liver and its subsequent complications. NAFLD or non-alcoholic fatty liver disease is believed to be responsible for conditions like liver cirrhosis and liver cancer and its patients are increasing worldwide. CSIR-CDRI has developed this drug under the Phytopharmaceutical mode of the Drug Controller General of India and has got the approval for Phase III clinical trials. The trial will be conducted at six hospitals… at AIIMS Delhi, ILBS Delhi, PGIMER Chandigarh, KEM Mumbai, NIMS Hyderabad and KGMU Lucknow in collaboration with ICMR New Delhi. This drug can provide a perfect indigenous solution against this serious disease.
